Target: EGFR
The epidermal growth factor receptor (EGFR; ERBB1; HER1) is an important target in oncology as its overexpression may lead to uncontrolled cell growth.
Today, there are kinase inhibitors and monoclonal antibodies that are used as therapies in cancers ranging from adenocarcinoma to glioblastoma. As always, there’s still room for improvement.
So, we’ve made our own using AI.
One of our best candidates (TUPEGFR-003, in yellow) versus cetuximab (in grey). EGFR shown in white.
Various binding affinity metrics from existing therapeutic anti-EGFR antibodies versus our diffused candidates.
We have a winner!
(Well, a runner-up…)
Recently, AdaptyvBio ran a 2nd round of their Protein Design Competition where protein designers could submit novel binders to EGFR.
1,131 novel designs were submitted by 130 groups using a variety of methods, of which 400 were selected and synthesized. (5 of ours were in the top 400.)
Our fully AI-generated antibody Fab TUPEGFR-012 came in at number 20 and was shown to bind to EGFR with a KD affinity >1.0e-5 M!
